Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 275 entries
View as:

An Observational Study of Cetrotide® Gonadotropin-releasing Hormone Antagonist (GnRH Antagonist) With GONAL-f® in Assisted Reproductive Technologies (ART)

Phase: N/A Priority: Normal
NCT ID: NCT01109654 Org: User:
Start: 09/30/08 End: 12/31/10 Due: 12/31/11

A Randomised, Phase II, Comparative Study With a Parallel Control for Evaluating the Efficacy and Safety of Combined Treatment of Lutropin Alpha and Recombinant Human Luteinizing Hormone in the Middle of the Controlled Ovarian Stimulation Follicular Phase in Women With Reduced Ovarian Reserve

Phase: N/A Priority: Normal
NCT ID: NCT01110707 Org: User:
Start: 01/10/05 End: 11/15/06 Due: 11/15/07

Study to Evaluate if the Addition of r-hLH (Luveris®) to FSH From Day 8 of Ovarian Stimulation is Able to Decrease Total FSH Dose and to Improve Cycle Outcome in Infertile Women Undergoing ART, Who Required High FSH Dose in a Previous Cycle

Phase: N/A Priority: Normal
NCT ID: NCT01071200 Org: User:
Start: 03/31/05 End: 04/30/09 Due: 04/30/10

An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment

Phase: N/A Priority: Normal
NCT ID: NCT01074333 Org: User:
Start: 09/30/08 End: 01/31/12 Due: 01/31/13

A Study to Assess the Food Effect on Bioavailability of Metformin/Gliclazide in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT03467971 Org: User:
Start: 03/06/18 End: 04/22/18 Due: 04/22/19

MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS)

Phase: N/A Priority: Normal
NCT ID: NCT02949908 Org: User:
Start: 02/09/17 End: 08/25/17 Due: 08/25/18

An Observational, Retrospective, UK & Ireland Audit of Patient Adherence to Rebif® Injections Using the RebiSmart™ Injection Device

Phase: N/A Priority: Normal
NCT ID: NCT01601080 Org: User:
Start: 04/30/12 End: - Due: -

EMD 521873 in Advanced Solid Tumors, MTD Finding

Phase: N/A Priority: Normal
NCT ID: NCT01032681 Org: User:
Start: 12/31/06 End: 01/31/12 Due: 01/31/13

Predictive Factors of Ovarian Response in Ovulation Induction With Intrauterine Insemination of a Gonal-f Low-dose Regimen

Phase: N/A Priority: Normal
NCT ID: NCT01100346 Org: User:
Start: 01/31/10 End: 09/30/10 Due: 09/30/11

EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01012102 Org: User:
Start: 04/30/08 End: 09/30/11 Due: 09/30/12

Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study of M5049 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT03676322 Org: User:
Start: 09/20/18 End: 07/26/19 Due: 07/26/20

Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)

Phase: N/A Priority: Normal
NCT ID: NCT00148798 Org: User:
Start: 10/31/04 End: 05/31/12 Due: 05/31/13

Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen®

Phase: N/A Priority: Normal
NCT ID: NCT01187550 Org: User:
Start: 03/31/07 End: 04/30/09 Due: 04/30/10

L-PZQ ODT in Schistosoma Infected Children

Phase: N/A Priority: Normal
NCT ID: NCT03845140 Org: User:
Start: 09/02/19 End: 10/11/21 Due: 10/11/22

Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in Diabetic Peripheral Neuropathy Pain Management

Phase: N/A Priority: Normal
NCT ID: NCT01364298 Org: User:
Start: 04/30/11 End: 07/31/12 Due: 07/31/13

Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02156466 Org: User:
Start: 08/31/14 End: 08/31/15 Due: 08/31/16

A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT01075763 Org: User:
Start: 11/30/04 End: 05/31/08 Due: 05/31/09

First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study

Phase: N/A Priority: Normal
NCT ID: NCT01419249 Org: User:
Start: 09/30/11 End: 10/31/12 Due: 10/31/13

A Retrospective Study to Understand the Clinical Management of Subjects With Multiple Sclerosis at a Site in Taiwan Over the Last 10 Years

Phase: N/A Priority: Normal
NCT ID: NCT01084798 Org: User:
Start: 08/31/08 End: 11/30/09 Due: 11/30/10

Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)

Phase: N/A Priority: Normal
NCT ID: NCT00154102 Org: User:
Start: 05/31/04 End: 03/31/11 Due: 03/31/12

Relative Bioavailability of Two Tepotinib Film-Coated Tablet Formulations in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT03021642 Org: User:
Start: 01/31/16 End: 03/31/16 Due: 03/31/17

Lutropin Alfa in Women at Risk of Poor Response

Phase: N/A Priority: Normal
NCT ID: NCT01112358 Org: User:
Start: 12/07/05 End: 01/30/07 Due: 01/30/08

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

Phase: N/A Priority: Normal
NCT ID: NCT01285401 Org: User:
Start: 02/28/11 End: 05/31/15 Due: 05/31/16

Bioequivalence Trial of Liquid Versus Freeze-Dried Pergoveris® in Pituitary Suppressed Healthy Premenopausal Female Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02317809 Org: User:
Start: 01/31/15 End: 10/31/15 Due: 10/31/16

A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone

Phase: N/A Priority: Normal
NCT ID: NCT01142466 Org: User:
Start: 12/31/05 End: 01/31/10 Due: 01/31/11